









Markets
/
Stocks
/
nasdaq-glmd
/

Galmed Pharmaceuticals Ltd

GLMD

0.664USD

+0.069+11.58%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.64MMarket Cap

LossP/E TTM



Galmed Pharmaceuticals Ltd

0.664

+0.069+11.58%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Galmed Pharmaceuticals Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Galmed Pharmaceuticals Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 209 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 0.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Galmed Pharmaceuticals Ltd's Score

Industry at a Glance

Industry Ranking

209 / 392

Overall Ranking

423 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Galmed Pharmaceuticals Ltd Highlights

StrengthsRisks

Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.

Overvalued

The company’s latest PE is -0.19, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 75.39K shares, decreasing 31.56% quarter-over-quarter.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Galmed Pharmaceuticals Ltd is 6.02, ranking 299 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.02

Change



Financials

4.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Galmed Pharmaceuticals Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Galmed Pharmaceuticals Ltd is 6.73, ranking 231 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.19, which is -27.23% below the recent high of -0.14 and -8927.69% above the recent low of -17.44.

Score

Industry at a Glance

Previous score

6.73

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 209/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Galmed Pharmaceuticals Ltd is 6.00, ranking 340 out of 392 in the Biotechnology & Medical Research industry.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

0.000

Target Price

0.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Galmed Pharmaceuticals Ltd

GLMD

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Galmed Pharmaceuticals Ltd is 2.41, ranking 377 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.83 and the support level at 0.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.30

Change

0.11

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.023

Sell

RSI(14)

37.682

Neutral

STOCH(KDJ)(9,3,3)

14.855

Neutral

ATR(14)

0.058

High Vlolatility

CCI(14)

-95.272

Neutral

Williams %R

73.804

Sell

TRIX(12,20)

-0.952

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.646

Buy

MA10

0.714

Sell

MA20

0.765

Sell

MA50

0.867

Sell

MA100

1.101

Sell

MA200

1.338

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Citadel Advisors LLC

50.49K

Baharaff (Allen)

36.94K

+31.44%

Two Sigma Investments, LP

21.20K

Nehemya (Guy)

6.28K

+20164.52%

Stenzler (Yohai)

6.28K

+20164.52%

Cohen (Doron)

6.25K

+36664.71%

Nir (Shmuel)

3.40K

+1148.16%

Sidransky (David)

3.12K

+7338.10%

Poshinski (Amir)

3.12K

UBS Financial Services, Inc.

963.00

-86.05%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Galmed Pharmaceuticals Ltd is 1.76, ranking 284 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.40. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.